The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies

Nathan M Radcliffe Ophthalmology, New York University, New York, NY, USA Abstract: Glaucomatous optic atrophy is the second most common cause of blindness worldwide, and lowering intraocular pressure (IOP) is the only proven method to slow or stop the progression of the disease. Approximately 40%...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Radcliffe NM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/5aef8b2261c0435b9664d2c60ef48a3e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5aef8b2261c0435b9664d2c60ef48a3e
record_format	dspace
spelling	oai:doaj.org-article:5aef8b2261c0435b9664d2c60ef48a3e2021-12-02T02:48:15ZThe impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies1177-5483https://doaj.org/article/5aef8b2261c0435b9664d2c60ef48a3e2014-12-01T00:00:00Zhttp://www.dovepress.com/the-impact-of-timolol-maleate-on-the-ocular-tolerability-of-fixed-comb-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483 Nathan M Radcliffe Ophthalmology, New York University, New York, NY, USA Abstract: Glaucomatous optic atrophy is the second most common cause of blindness worldwide, and lowering intraocular pressure (IOP) is the only proven method to slow or stop the progression of the disease. Approximately 40% of patients with elevated IOP will require more than one medication to obtain a modest 20% reduction in IOP, and as a result, some patients may require two medications, provided in either two separate bottles or in one bottle with the use of fixed-combination therapies. Each therapy has its own unique safety and efficacy profile. Topical beta-blockers have a particularly favorable ocular-tolerability profile, and several studies of fixed-combination medications containing the beta-blocker timolol maleate have shown a lower prevalence of some ocular adverse events for the fixed-combination therapy compared to the non-beta-blocker individual component. In this review, we examined clinical data pertaining to the ocular surface tolerability of fixed-combination medications containing timolol maleate in comparison to the individual components. In particular, preference was given to prospective, randomized, multicenter trials of 3 months in duration or longer that compared a fixed-combination therapy to monotherapy with the individual components. A review of the literature revealed that some fixed-combination therapies can provide a reduced risk of common side effects compared to their individual components, with conjunctival hyperemia and ocular allergy being less frequent in some timolol-containing fixed-combination therapies. This effect appears to be most significant for latanoprost 0.005%, bimatoprost 0.03%, and brimonidine 0.2%. Keywords: bimatoprost, brimonidine, hyperemia, latanoprost, ocular allergyRadcliffe NMDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2014, Iss default, Pp 2541-2549 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Radcliffe NM The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies
description	Nathan M Radcliffe Ophthalmology, New York University, New York, NY, USA Abstract: Glaucomatous optic atrophy is the second most common cause of blindness worldwide, and lowering intraocular pressure (IOP) is the only proven method to slow or stop the progression of the disease. Approximately 40% of patients with elevated IOP will require more than one medication to obtain a modest 20% reduction in IOP, and as a result, some patients may require two medications, provided in either two separate bottles or in one bottle with the use of fixed-combination therapies. Each therapy has its own unique safety and efficacy profile. Topical beta-blockers have a particularly favorable ocular-tolerability profile, and several studies of fixed-combination medications containing the beta-blocker timolol maleate have shown a lower prevalence of some ocular adverse events for the fixed-combination therapy compared to the non-beta-blocker individual component. In this review, we examined clinical data pertaining to the ocular surface tolerability of fixed-combination medications containing timolol maleate in comparison to the individual components. In particular, preference was given to prospective, randomized, multicenter trials of 3 months in duration or longer that compared a fixed-combination therapy to monotherapy with the individual components. A review of the literature revealed that some fixed-combination therapies can provide a reduced risk of common side effects compared to their individual components, with conjunctival hyperemia and ocular allergy being less frequent in some timolol-containing fixed-combination therapies. This effect appears to be most significant for latanoprost 0.005%, bimatoprost 0.03%, and brimonidine 0.2%. Keywords: bimatoprost, brimonidine, hyperemia, latanoprost, ocular allergy
format	article
author	Radcliffe NM
author_facet	Radcliffe NM
author_sort	Radcliffe NM
title	The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies
title_short	The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies
title_full	The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies
title_fullStr	The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies
title_full_unstemmed	The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies
title_sort	impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/5aef8b2261c0435b9664d2c60ef48a3e
work_keys_str_mv	AT radcliffenm theimpactoftimololmaleateontheoculartolerabilityoffixedcombinationglaucomatherapies AT radcliffenm impactoftimololmaleateontheoculartolerabilityoffixedcombinationglaucomatherapies
_version_	1718402162517606400

The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies

Ejemplares similares